Cullinan Therapeutics, Inc. (NASDAQ:CGEM) disclosed detailed Phase 3 REZILIENT3 results on September 13, 2026, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Zipalertinib plus chemotherapy achieved median progression-free survival of 14.5 months, compared with 8.5 months for chemotherapy alone.
Progression-free survival, or PFS, measures time until disease progression or death. The six-month difference supports better disease control, while the safety results raise a substantial treatment-burden question: grade 3 or higher adverse events occurred in 87.1% of combination recipients versus 54.4% of controls.
Bull Case
The randomized trial provides persuasive efficacy evidence for Cullinan Therapeutics, Inc.. At the planned interim analysis, the PFS hazard ratio was 0.50, indicating an estimated 50% reduction in the hazard of progression or death. The primary endpoint result was statistically significant.
Objective response rates, measuring the proportion of patients whose tumors shrank sufficiently to meet response criteria, were 65.0% with the combination and 40.3% with chemotherapy. That improvement reinforces the disease-control result.
For patients facing advanced cancer, delaying progression can be valuable even before an overall-survival advantage is established. Commercial uptake would depend on whether clinicians and patients consider the extra time without progression worth the additional monitoring and side effects.
The financial opportunity extends through a collaboration with an affiliate of Taiho Pharmaceutical Co., Ltd. Cullinan Therapeutics, Inc. is entitled to 50% of potential U.S. pre-tax profits from zipalertinib, subject to contractual adjustments. The partners share agreed-upon development costs equally. Successful first-line commercialization could therefore create an earnings stream alongside the broader development pipeline.
Bear Case
The safety burden is material. Grade 3 or higher hematologic adverse events occurred in 58.6% of combination recipients versus 28.7% of controls. These blood-related toxicities could require additional monitoring, supportive care, or treatment modifications.
For Cullinan Therapeutics, Inc., the commercial implications depend on how that burden affects treatment persistence. Dose reductions, interruptions, discontinuations, and patient-reported quality of life would help establish how much of the efficacy benefit patients can sustain in practice.
Overall-survival data remained immature at 30% event maturity. Longer life has not yet been established. Continued follow-up will help clarify whether better disease control translates into a survival advantage.
Competition also matters. Amivantamab with carboplatin and pemetrexed already has FDA approval for first-line treatment in this molecularly defined population. REZILIENT3 compared the investigational combination with chemotherapy alone, so it does not establish superiority over that approved regimen.
An oral targeted component may offer practical appeal, but the combination still requires chemotherapy. Prescribing decisions would weigh efficacy, toxicity, treatment logistics, and access together. Zipalertinib remains investigational, and regulatory assessment is still an essential step.
Hedge Fund Sentiment
The filings available so far reflect positions held before Cullinan Therapeutics, Inc. reported its detailed Phase 3 REZILIENT3 results. Insider Monkey’s database showed 35 hedge funds holding Cullinan Therapeutics, Inc. at the end of 2Q2026, unchanged from three months earlier.
Conclusion
Cullinan Therapeutics, Inc. has a convincing PFS result, but adoption will depend on the full benefit-risk profile. Longer survival follow-up, treatment persistence, quality-of-life findings and regulatory decisions are the next tests. Commercial success requires an effective regimen that patients can tolerate and clinicians can position against existing options.
READ NEXT: CBRE Group (CBRE) Unit Buys $1.6 Billion Net-Lease Platform. Can Scale Lift Fee Earnings? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center